Adverum Biotechnologies Inc. initiated an underwritten public offering of its common shares.
The company also plans to grant the underwriters an option to buy up to an additional 15% of the common shares.
Cowen and Piper Jaffray & Co. are acting as joint book-running managers and Raymond James is acting as lead manager for the proposed offering.
